Voluntary exercise alleviates neural functional deficits in Parkinson's disease mice by inhibiting microglial

Jinghui Xu1, Xiaofei He1, Lili Li1

  • 1Department of Rehabilitation Medicine, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

PubMed

Insights

Physical exercise inhibits microglial ferroptosis in Parkinson's disease. Exercise upregulates SLC7A11, suppressing ALOX12, which enhances the clearance of alpha-synuclein and improves neurological function.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Pathology

Background:

  • Microglia are vulnerable to ferroptosis, impairing their function in Parkinson's disease (PD).
  • Physical exercise (PE) shows promise in reducing alpha-synuclein (α-syn) pathology in PD, but its effect on microglial ferroptosis is unknown.

Purpose of the Study:

  • To investigate the impact of physical exercise on microglial ferroptosis.
  • To elucidate the molecular mechanisms by which exercise modulates microglial ferroptosis and alpha-synuclein clearance in PD.

Main Methods:

  • Utilized a mouse model of Parkinson's disease.
  • Assessed the effects of voluntary physical exercise on microglial ferroptosis markers.
  • Investigated the expression of SLC7A11 and ALOX12 in response to exercise.
  • Evaluated microglial phagocytosis and alpha-synuclein clearance.
  • Monitored neurological function in exercising PD mice.

Main Results:

  • Voluntary physical exercise effectively inhibits microglial ferroptosis.
  • Exercise upregulates solute carrier family 7 member 11 (SLC7A11), which suppresses arachidonate 12-lipoxygenase (ALOX12).
  • This inhibition of ferroptosis enhances microglial phagocytosis and clearance of alpha-synuclein, leading to improved neurological function in PD mice.

Conclusions:

  • Microglial ferroptosis plays a crucial role in Parkinson's disease progression.
  • Physical exercise attenuates microglial ferroptosis through the SLC7A11/ALOX12 pathway.
  • Targeting microglial ferroptosis presents a potential therapeutic strategy for Parkinson's disease.